Beam adds to drug delivery stable with USD 120 Million GuideTx buy
Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases.
Beam announced that it paid USD 120 million upfront to acquire Guide Therapeutics in an all-stock agreement.
The gene-editing technologies, which have reached the clinic, CRISPR, zinc finger nucleases, and TALENs, make their edits by nicking DNA at the target site. Cambridge, Massachusetts-based Beam aims to make more precise edits with genetic medicines, which employ base-editing. Instead of snipping the genome...
